Sorrento Therapeutics (SRNE) Competitors $0.0008 0.00 (-33.33%) (As of 12/20/2024 05:32 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOptions ChainSEC FilingsSustainabilityTrends SRNE vs. SPRC, DRMA, CMND, CYCC, APVO, GLMD, AKAN, BON, SLRX, and ATNFShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include SciSparc (SPRC), Dermata Therapeutics (DRMA), Clearmind Medicine (CMND), Cyclacel Pharmaceuticals (CYCC), Aptevo Therapeutics (APVO), Galmed Pharmaceuticals (GLMD), Akanda (AKAN), Bon Natural Life (BON), Salarius Pharmaceuticals (SLRX), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. SciSparc Dermata Therapeutics Clearmind Medicine Cyclacel Pharmaceuticals Aptevo Therapeutics Galmed Pharmaceuticals Akanda Bon Natural Life Salarius Pharmaceuticals 180 Life Sciences SciSparc (NASDAQ:SPRC) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has preferable valuation & earnings, SPRC or SRNE? SciSparc has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.75M1.26-$5.12MN/AN/ASorrento Therapeutics$60.32M0.01-$572.84MN/AN/A Does the media refer more to SPRC or SRNE? In the previous week, SciSparc had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Sorrento Therapeutics. SciSparc's average media sentiment score of 1.00 beat Sorrento Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sorrento Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SPRC or SRNE more profitable? Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Sorrento Therapeutics N/A N/A N/A Does the MarketBeat Community favor SPRC or SRNE? Sorrento Therapeutics received 608 more outperform votes than SciSparc when rated by MarketBeat users. Likewise, 68.77% of users gave Sorrento Therapeutics an outperform vote while only 66.67% of users gave SciSparc an outperform vote. CompanyUnderperformOutperformSciSparcOutperform Votes266.67% Underperform Votes133.33% Sorrento TherapeuticsOutperform Votes61068.77% Underperform Votes27731.23% Which has more volatility and risk, SPRC or SRNE? SciSparc has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Do institutionals & insiders have more ownership in SPRC or SRNE? 25.1% of SciSparc shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummarySciSparc and Sorrento Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$441,000.00$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E RatioN/A46.7389.5817.17Price / Sales0.01415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book-0.023.894.774.78Net Income-$572.84M-$42.21M$120.15M$225.60M7 Day PerformanceN/A-2.15%-1.92%-1.23%1 Month PerformanceN/A4.20%11.47%3.36%1 Year PerformanceN/A18.39%30.54%16.60% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento TherapeuticsN/A$0.00-33.3%N/A-97.3%$441,000.00$60.32M0.00800Analyst ForecastGap DownSPRCSciSparc1.1491 of 5 stars$0.23-14.4%N/A-95.6%$2.41M$2.88M0.004DRMADermata Therapeutics2.5691 of 5 stars$1.10+0.9%$6.00+445.5%-89.1%$2.25MN/A-0.078Gap UpCMNDClearmind Medicine0.4717 of 5 stars$1.32-10.4%N/A-60.0%$2.24MN/A0.00N/ACYCCCyclacel Pharmaceuticals2.304 of 5 stars$0.35-3.1%$11.00+3,042.9%-90.1%$2.20M$74,000.00-0.0414Analyst ForecastAPVOAptevo Therapeutics2.0482 of 5 stars$4.17+2.0%$10,952.00+262,537.9%-100.0%$2.13M$3.11M0.0050Gap UpHigh Trading VolumeGLMDGalmed Pharmaceuticals0.4234 of 5 stars$3.25+9.4%N/A-36.5%$2.08MN/A-0.2020Gap UpAKANAkandaN/A$1.42-4.7%N/A-95.6%$2.03M$2.51M0.00110BONBon Natural LifeN/A$1.72+1.2%N/A-74.2%$2.02M$25.56M0.00100SLRXSalarius PharmaceuticalsN/A$1.40-5.1%N/A-68.8%$2.01M$1.84M-0.1820Gap UpATNF180 Life SciencesN/A$1.84-4.7%N/A-44.7%$1.89MN/A0.007News Coverage Related Companies and Tools Related Companies SciSparc Competitors Dermata Therapeutics Competitors Clearmind Medicine Competitors Cyclacel Pharmaceuticals Competitors Aptevo Therapeutics Competitors Galmed Pharmaceuticals Competitors Akanda Competitors Bon Natural Life Competitors Salarius Pharmaceuticals Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRNE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
